Medivir to present at the Stockholm Corporate Finance Life Science Day

Medivir AB (Nasdaq Stockholm: MVIR) will participate in the Stockholm Corporate Finance Life Science Day on March 9, 2023.

Rhea-AI Summary

Medivir AB (Nasdaq Stockholm: MVIR) will participate in the Stockholm Corporate Finance Life Science Day on March 9, 2023. CEO Jens Lindberg is set to present the company's ongoing clinical study with fostroxacitabine bralpamide (fostrox) at 08:30 CET. The presentation will be accessible on Medivir's website post-event. Medivir focuses on developing innovative cancer treatments addressing significant unmet medical needs, particularly targeting liver cancer cells to minimize side effects. The company collaborates with partners, including IGM Biosciences (Nasdaq: IGMS), for further drug development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, March 8, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Stockholm Corporate Finance Life Science Day on March 9, 2023.

CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox) at 08.30 CET.

The presentation will be available after the meeting on Medivirs website; www.medivir.com.

For additional information, please contact

Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com

Medivir in brief

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

The following files are available for download:

https://mb.cision.com/Main/652/3729810/1900008.pdf

Press release (PDF)

 

View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-stockholm-corporate-finance-life-science-day-301765871.html

SOURCE Medivir

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Medivir AB's participation in the Stockholm Corporate Finance Life Science Day?

Medivir AB will present its ongoing clinical study with fostroxacitabine bralpamide on March 9, 2023.

When will the CEO of Medivir present at the Life Science Day?

CEO Jens Lindberg will present at 08:30 CET on March 9, 2023.

What is the focus of Medivir AB's drug development?

Medivir AB focuses on developing innovative cancer treatments, particularly targeting unmet medical needs in liver cancer.

How is IGM Biosciences related to Medivir AB?

IGM Biosciences collaborates with Medivir AB, exclusively licensing Birinapant for solid tumor treatments.

Where can I find the presentation from Medivir's CEO?

The presentation will be available on Medivir's website after the event.